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Abstract
Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-modified peptide HIV fusion inhibitor that can irreversibly
conjugate to serum albumin. Previous studies demonstrated its in vivo long half-life and potent anti-HIV activity. Here, we
focused to characterize its biophysical properties and evaluate its antiviral spectrum. In contrast to T20 (Enfuvirtide, Fuzeon),
ABT was able to form a stable a-helical conformation with the target sequence and block the fusion-active six-helix bundle
(6-HB) formation in a dominant-negative manner. It efficiently inhibited HIV-1 Env-mediated cell membrane fusion and virus
entry. A large panel of 42 HIV-1 pseudoviruses with different genotypes were constructed and used for the antiviral
evaluation. The results showed that ABT had potent inhibitory activity against the subtypes A, B and C that predominate the
worldwide AIDS epidemics, and subtype B9, CRF07_BC and CRF01_AE recombinants that are currently circulating in China.
Furthermore, ABT was also highly effective against HIV-1 variants resistant to T20. Taken together, our data indicate that the
chemically modified peptide ABT can serve as an ideal HIV-1 fusion inhibitor.
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Introduction
HIV-1 envelope glycoprotein (Env) complex, which is com-
posed of three receptor-binding gp120 subunits and three fusion
protein gp41 subunits, mediates virus entry by fusing viral and
cellular membranes and offers an attractive target for developing
antiviral agents. During the fusion reaction, N- and C-terminal
heptad repeat regions (NHR and CHR) of the gp41 ectodomain
refold into a thermostable six-helix bundle structure (6-HB),
representing a fusion-active conformation that can bridge the viral
and cellular membranes for the merger [1–4]. A number of
peptides derived from the gp41 CHR (C-peptides) can specifically
inhibit viral entry at low nanomolar concentration, such as C34,
T20 [5–9]. It is thought that C-peptides act by competitive binding
to the NHR of gp41 during its conformational change to the
fusogenic state (i.e. pre-hairpin conformation) and hence block the
6-HB formation in a dominant-negative manner [6–7,10]. T20
(Enfuvirtide, Fuzeon) has been successfully developed as the first
and only HIV-1 fusion inhibitor for clinical use [11–12]. However,
peptide drugs usually suffer from their short in vivo half-life and
require frequent injections. Being a 36-mer peptide, T20 has an in
vivo half-life of 3.46 to 4.35 h and is given twice-daily at a high-
dosage [13]. Therefore, development of long-acting anti-HIV
peptide drugs is highly intriguing.
In succession to T20, a number of design strategies have been
applied to develop new peptide-based fusion inhibitors with
improved stability, bioavailability and potency [5–7,14–18]. For
example, several potent inhibitors were designed by introducing
intra-helical salt-bridges that can stabilize the peptides [16–17,19].
T2635, a third generation peptide inhibitor is highly active against
HIV-1 escape variants [17–18]. It is believed that the charged
residues within T2635 are ‘‘masked’’ by introduced salt bridges
thus overcoming the resistance by mechanism of charge-repulsion
[14,17,20]. Another successful example is Sifuvirtide (SFT), an
electrostatically constrained peptide inhibitor showing potent anti-
HIV activity, good safety and pharmacokinetic profiles, and is
currently under Phase II clinical trials [16,21]. Recently, peptide-
fatty acid and cholesterol conjugates with dramatically improved
inhibitory activity and pharmacokinetics have been reported [22–
23]. It was hypothesized that the incorporation of fatty acid or
cholesterol can target the peptide inhibitors to viral or cellular
membranes thereby increasing the drug concentration at the site
of membrane fusion. Prominently, the cholesterol-conjugated
peptide C34 had dramatically increased serum lifetime in mice
[23]. Stoddart et al [24] reported that human serum albumin
(HSA)-conjugated peptides (T20 and C34) possessed equipotent in
vitro anti-HIV activity compared to the original peptides and
sustained activity in vivo.
Albuvirtide (ABT) is a 3-maleimimidopropionic acid (MPA)-
modified peptide designed with C34 sequence as a template (Fig. 1)
[25]. In which, the 13th residue serine (S) was changed to lysine
(K) which allows a single MPA modification at this position. Other
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32599two residues not involved in target binding were substituted by
glutamic acid (E) to improve the solubility, stability and antiviral
activity. The engineered peptide can covalently link to serum
albumin at a 1:1 molecular ratio through an irreversible
conjugation reaction between the maleimide and free thiol groups
[25]. Previous studies demonstrated that upon intravenous
injection ABT could rapidly form conjugates with serum albumin
and dramatically extend its in vivo half-life from 1.67 h to 25.8 h in
rats and from 10.89 h to 102.4 h in monkeys [25]. Importantly,
ABT had potent in vivo anti-HIV efficacy as shown by a SCID-
huThy/Liv mouse infection model, highlighting its potential to
become a new generation HIV-1 fusion inhibitor. A Phase I
clinical trial is under way to evaluate its safety, tolerability and
pharmacokinetic profiles in humans. In this parallel leading study,
we are interested in characterizing its biophysical properties and
antiviral spectrum. Our results demonstrated that the chemically
modified ABT could form a stable helical structure with the target
sequence and efficiently block 6-HB formation and HIV-1 Env-
mediated cell-cell fusion. Prominently, it inhibited viral entry by
diverse HIV-1 subtypes and variants, including the subtypes A, B
and C that predominate the worldwide AIDS epidemics, and
subtype B9, CRF07_BC and CRF01_AE recombinants that are
currently circulating in China, and HIV-1 variants resistant to
T20. The data provide critical information for developing new
HIV-1 fusion inhibitors for clinical use.
Results
Biophysical characterization of ABT
To clarify whether the MPA modification affects the secondary
structure of ABT, we examined its interaction with the NHR
target sequence (N36) using CD spectroscopy. C34 and T20 were
included as control peptides. As shown in Fig. 2, the CD spectra of
C-peptides alone (ABT, T20 and C34) did not show a minimum at
222 nm, suggesting their minimum a-helical conformation. In the
presence of N36, the CD spectra of both ABT and C34 displayed
a double minimum at 208 and 222 nm, suggesting that the
interactions of C- and N-peptides induced the formation of
secondary a-helical structures. Apparently, the ABT/N36 com-
plex had a relatively higher a-helicity than C34/N36 complex.
Consistent with our previous studies, T20 could not form a typical
a-helical complex with N36 as indicated by the lack of minimum
at 208 and 222 nm. To determine the binding affinity of ABT to
N36, we measured the thermal stability of the ABT/N36 helical
complex. The sigmoidal transition of the CD signal at 222 nm
correlates with the thermal stability of the helical complexes
formed from C- and N-peptides, which in turn reflects the binding
affinity of these peptides. Fig. 2B shows the CD thermal
denaturation curves of C-peptides and N36 complexes. Compared
to the C34/N36 (Tm=54uC), the ABT/N36 had a slightly
improved thermal stability (Tm=56uC) while the T20/N36
mixture was undetectable.
Further, we used an ITC assay to determine the interaction
between C-peptides and N36. Consistently, both ABT and C34
could specifically interact with N36 in our experimental conditions
(Fig. 3). In contrast, T20 could not efficiently interact with N36 as
manifested by its low Kd value compared to ABT and C34. Such
biophysical characteristics of ABT indicate that this MPA-
modified peptide maintains its normal structure to form a-helical
interactions with the N-helices.
Inhibition of ABT on 6-HB formation, cell fusion, viral
entry and replication
To elucidate the mechanism of action of ABT, we checked
whether ABT can physically block the formation of 6-HB as
modeled by the N36 and C34 peptides described previously
[16,26]. As shown in Fig. 4A, both ABT and C34 were able to
inhibit the formation of 6-HB in a dose-dependent fashion, but the
former exhibited significantly higher potency than C34 as
manifested by its IC50 value of 0.82 mM compared with
Figure 1. Schematic illustration of HIV-1 gp41 and peptide fusion inhibitors. A. View of the gp41 functional regions. The residue numbers
of each region correspond to their positions in gp160 of HIV-1HXB2. FP, fusion peptide; NHR, N-terminal heptad repeat; CHR, C-terminal heptad repeat;
TM, transmembrane domain. B. Sequence of CHR-derived anti-HIV-1 peptides. ABT is engineered with three amino acids different from C34 (marked
in bold). The 13th residue serine (S) of C34 was changed to lysine (K) which allows a single modification by 3-maleimidopropionic acid (MPA).
doi:10.1371/journal.pone.0032599.g001
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a concentration as high as 20 mM. These results were consistent
with our observations from CD studies and demonstrated that
ABT acts in a mechanism of blocking 6-HB formation in a
dominant-negative manner. Further, we examined the inhibitory
activity of ABT on HIV-1HXB2 Env-mediated cell-cell membrane
fusion. As shown in Fig. 4B, ABT could inhibit the fusion with an
IC50 of 1.27 nM, while C34 and T20 inhibited the fusion with
IC50 values of 3.86 nM and 56.22 nM, respectively.
Next, we tested ABT and T20 for their inhibitory activity on the
viral cell entry mediated by HIV-1NL4-3 Env-pseudotyped virus. As
shown in Fig. 5A, ABT could efficiently inhibit the virus entry with
a mean IC50 at 2.19 nM, whereas T20 worked with much less
efficiency (IC50=70.74 nM). Similarly, ABT had much potent
inhibitory activity on the replication of wild-type HIV-1NL4-3
(Fig. 5B). In addition, we assessed ABT for its antiviral activity in
the presence of serum components. The peptide was mixed with
various concentrations (5, 10, 20 and 50%) of human sera freshly
isolated from a HIV-seronegative healthy volunteer and incubated
for 2 h at 37uC. The mixture was then diluted with a DMEM-
based complete medium supplemented with 10% FCS and
subjected to the single-cycle infection assay. From Fig. 6 we can
see that the HIV-inhibitory activity of ABT was not influenced by
high concentration of human sera (up to 50%).
Potent inhibition of ABT on HIV-1 subtypes that
dominate the AIDS epidemics worldwide
HIV-1 evolves with the great genetic diversity and can be
classified into three major groups: M (major), O (outlier) and N
(non-M non-O or new) [27–28]. The M group viruses that cause
the vast majority of HIV-1 pandemic can be further divided into
many subtypes, including A–D, F–H, J and K, as well as several
circulating and unique recombinant forms (CRFs and URFs). The
sequence diversity has raised concerns over the peptide fusion
inhibitors that target the highly variable envelope region. Here, we
firstly evaluated ABT for its antiviral activity with a panel of 14
HIV-1 pseudoviruses with their Envs derived from subtypes A, B
and C. As shown in Table 1, ABT had potent inhibitory activity
against the cellular entry by these diverse viruses. It inhibited
subtype A, B and C viruses with mean IC50 values at 6.3 nM,
27.41 nM and 2.92 nM respectively. In comparison, T20 showed
much weak inhibition on these three subtypes, with mean IC50 at
14.47 nM, 214.04 and 55.18 nM respectively. Compared to other
HIV-1 isolates, some Envs derived from the subtype B were much
less sensitive to both ABT and T20, but sequence analysis did not
identify the previously known resistance mutations in the NHR
and CHR of gp41.
Potent inhibition of ABT on HIV-1 variants that are
predominantly circulating in China
Because ABT has been approved for Phase I clinical trials, we
are interested to know the inhibitory activity of ABT on HIV-1
strains that are currently circulating in China. Two recombinant
forms, CRF07_BC and CRF01_AE, and subtype B9 are
predominant viruses, accounting for infections at 50.2%, 15.54%
and 29.11% respectively (with a total of ,95%) [29–30].
Therefore, we constructed a panel of 28 HIV-1 pseudoviruses
with their Envs derived from the above three subtypes and used in
single-cycle infection assays. The results have been presented in
Table 2. Compared to T20, ABT displayed more potent inhibitory
activity against the virus entry, with mean IC50 at 5.21 nM for
CRF07_BC, 6.93 nM for CRF01_AE, and 9.46 nM for B9. T20
inhibited three subtypes at 47.2 nM, 68.11 nM and 19.49 nM
respectively.
Potent inhibition of ABT on HIV-1 carrying mutations that
confer T20-resistance
Because there were significant differences in biophysical and
anti-HIV properties between ABT and T20, we sought to
determine whether ABT is able to inhibit HIV-1 strains resistant
to T20. Therefore, we generated a panel of HIV-1NL4-3 Env-based
pseudoviruses carrying single or double mutations that are
frequently emerged in T20- treated AIDS patients and approved
to confer T20-resistance (Table 3). Different from the majority of
Figure 2. Biophysical characterization of ABT by CD spectros-
copy. A. CD spectra of NHR and CHR-derived peptides and their
complexes. B. Thermostability of the complex formed by N36 and ABT
or C34. The unfolding temperature of each complex was scanned at
222 nm by CD spectroscopy, and their Tm values were calculated. The
final concentration of each peptide in PBS is 1 mM.
doi:10.1371/journal.pone.0032599.g002
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‘‘DIV’’ motif that is well known to confer T20-resistance.
Therefore, we calculated the resistance fold-changes by using
both the wild-type and D36G mutant as reference viruses
(Table 3). As expected, D36G mutant was more sensitive to T20
inhibition (8.3-fold) while not significantly changed to C34 and
ABT. Impressively, single or double mutations in the gp41 could
result in high level resistance to T20 and cross-resistance to C34.
Figure 3. Biophysical characterization of ABT by ITC assay. 2 mM N36 dissolved in ddH20 was injected into the chamber containing 200 mM
ABT, C34 or T20. The experiments were carried out at 25uC. Data acquisition and analysis were performed using MicroCal Origin software (version 7.0),
and show that ABT and C34 can efficiently interact with N36 but T20 not.
doi:10.1371/journal.pone.0032599.g003
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example, V38A or V38M single mutations and V38A/N42T
double mutations conferred high-fold resistance changes to T20
and C34 but much mild to ABT. We also chose two HIV-1NL4-3
molecular clones carrying L33S or I37V/V38T to evaluate ABT
and T20. The results showed that ABT was also highly effective on
these two infectious viruses. In a sharp contrast, T20 had no any
inhibitory activity at a concentration up to 750 nM. Therefore, the
present data highlight that ABT has a potent and broad anti-HIV
activity, not only for currently worldwide circulating subtypes but
also for the induced variants that are resistant to the first and
second generations of HIV-1 fusion inhibitors.
Discussion
ABT is a newly developed MPA-modified anti-HIV peptide that
can irreversibly conjugate to the serum albumin and extend its
half-life [25]. The previous studies had shown its in vivo longevity
and anti-HIV activity and pushed it in a Phase I clinical trial in
China. In the present study, we have finely characterized ABT by
using several approaches. Firstly, we analyzed its biophysical
properties by CD and ITC analyses. It is well known that the CD
spectra can reveal the presence of stable a-helical structures of the
NHR-CHR helical bundle that is thought to be mechanistically
and thermodynamically correlated with HIV-1 fusion [26,31].
The CD spectra typically at 222 nm indicated the inter-helical
interaction of ABT and N36, a NHR-derived peptide containing
the ABT target sequence. The a-helicity and thermostability of
ABT/N36 mixture were higher than that of C34/N36 mixture, a
core structure of fusion-active gp41 [1]. The high-affinity
interaction of ABT and N36 was further confirmed by ITC
experiments. These results suggested that the chemically modified
peptide fusion inhibitor ABT could maintain even improve its
normal structure and function. However, how the ABT/N36
Figure 4. Inhibition of ABT on 6-HB formation and cell
membrane fusion. A. ABT and C34 can efficiently inhibit 6-HB
formation in a dose-dependent manner, but T20 has no such effect. B.
Inhibition of HIV-1HXB2 Env-mediated cell-cell membrane fusion by ABT,
C34 and T20. The data were derived from the results of three
independent experiments and are expressed as means 6 standard
deviations.
doi:10.1371/journal.pone.0032599.g004
Figure 5. Inhibition of ABT on HIV-1 entry and replication. A.
Inhibition of HIV-1NL4-3 Env-pseudotyped virus in single-cycle assay that
demonstrates the virus-cell membrane fusion. B. Inhibition of wild-type
HIV-1NL4-3 replication. ABT shows significantly higher potency than T20
in inhibiting HIV-1NL4-3 entry and replication. The data were derived
from the results of three independent experiments and are expressed
as means 6 standard deviations.
doi:10.1371/journal.pone.0032599.g005
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need to be further characterized. One can speculate that mutated
residues or MPA molecules within ABT may determine the
difference.
The mechanism of action of HIV-1 peptide inhibitors derived
from the NHR and CHR has been considered to be a dominant-
negative manner, in which the exogenous peptides block the
formation of 6-HB structure through the competitive binding
[6,10]. In our previous studies, we developed an ELISA-based
system to test whether the peptide-based or small molecule-based
fusion inhibitors block the 6-HB formation, in which the mAb NC-
1 specific for the 6-HB was used as a capture and the biotinylated-
C34 was used for signal detection [26,32]. With this convenient
method we proved that ABT could efficiently block the 6-HB
formation. Together with the CD and ITC data, our studies
demonstrated that ABT acts like many other peptides through a
mechanism of 6-HB inhibition. Concomitant to its mechanism of
interacting with the NHR target and disrupting 6-HB, ABT had
potent inhibitory activity on HIV-1 Env-mediated cell-cell
membrane fusion and virus entry. We also demonstrated that
ABT could stably exert its strong anti-HIV-1 activity in freshly
Figure 6. Effect of human serum on the anti-HIV activity of
ABT. The human sera were freshly isolated from a HIV-seronegative
healthy volunteer. The peptide was mixed with various concentrations
(5, 10, 20 and 50%) of human sera freshly isolated from a HIV-
seronegative healthy volunteer and incubated for 2 h at 37uC. The
mixture was then diluted with a DMEM-based complete medium
supplemented with 10% FCS and subjected to the single-cycle infection
assay. The percent inhibition by ABT was calculated as described in the
materials and method. The data were derived from the results of three
independent experiments and are expressed as means 6 standard
deviations.
doi:10.1371/journal.pone.0032599.g006
Table 1. Inhibition of ABT on subtype A, B and C HIV-1
strains
a.
Pseudovirus Subtype CoR
b IC50 (nM)
ABT T20
92RW020 A R5 5.6562.17 25.3869.81
92UG037.8 A R5 6.9560.66 3.5560.95
SF162.LS B R5 12.7961.18 43.5569.16
AC10.0.29 B R5 5.6461.20 10.0760.45
TRO.11 B R5 35.1066.01 333.65648.86
REJO4541 B R5 3.1260.17 78.07611.26
RHPA4259 B R5 66.3964.47 281.9060.57
CAAN5342 B R5 63.0561.64 722.90653.46
SC422661.8 B R5 5.8160.51 28.1765.92
Du172.17 C R5 1.0160.39 11.6065.29
Du422.1 C R5 1.4660.26 28.4265.14
ZM197M.PB7 C R5 5.4260.71 63.30617.01
ZM109F.PB4 C R5 2.8960.78 76.3862.69
CAP45.2.00.G3 C R5 3.8360.19 96.2266.91
aThe inhibitory activity of each peptide was determined in triplicate by a single-
cycle infectivity assay. The data were derived from the results of three
independent experiments and are expressed as means 6 standard deviations.
bCo-R: coreceptor use.
doi:10.1371/journal.pone.0032599.t001
Table 2. Inhibition of ABT on CRF07_BC, CRF01_AE and
B’HIV-1 variants
a.
Pseudovirus Subtype
b CoR
c IC50 (nM)
ABT T20
CH064 B/C R5 2.3360.21 61.72612.54
CH070 B/C R5 6.2360.63 135.95636.42
CH091 B/C R5 2.8260.35 65.93614.28
CH110 B/C R5 2.8060.61 18.5763.15
CH119 B/C R5 6.7161.15 22.1162.74
CH120 B/C R5 16.0061.68 50.4364.22
BC02 B/C R5 1.5160.13 2.6060.48
BC03 B/C R5 3.5160.50 3.4660.41
BC05 B/C R5 5.9260.26 4.3960.25
BC07 B/C R5 5.4661.03 12.5261.58
BC14 B/C R5 3.4360.04 108.51652.63
BJ22-5 B/C R5 4.1060.22 25.7864.17
HB5-3 B/C R5 2.7060.40 23.1162.55
SC19-15 B/C R5 1.3160.10 7.6160.97
YN148r-9 B/C R5 16.8861.62 131.43614.74
XJ50-6 B/C R5 1.5960.17 81.08617.61
AE01 A/E R5 2.2661.01 24.8362.25
AE03 A/E R5 7.7960.27 7.8061.66
BJ5.11 A/E R5 17.0961.85 342.006132.09
SHX335.24 A/E R5 1.3360.34 51.0067.35
YN192.31 A/E R5 11.4161.84 68.5363.25
GX11.13 A/E R5 5.7861.00 6.6060.32
GX2010.36 A/E R5 4.3660.33 18.1463.75
GX2010.36H A/E R5 5.4360.45 25.9460.28
B01 B9 R5 2.1960.10 49.5062.41
B02 B9 R5 9.2561.00 8.5960.80
B04 B9 R5 18.1065.30 7.8060.43
43-22 B9 R5 8.2860.85 12.0763.24
aThe inhibitory activity of each peptide was determined in triplicate by a single-
cycle infectivity assay. The data were derived from the results of at least three
independent experiments and are expressed as means 6 standard deviations.
bHIV-1 subtypes: B/C, CRF07_BC; A/E, CRF01_AE; B9, Tai B.
cCo-R: coreceptor use.
doi:10.1371/journal.pone.0032599.t002
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manner that T20 does. Actually, the previous studies have
indicated that the anti-HIV activity of peptide-based fusion
inhibitors is not significantly influenced by serum components
[19,33].
One of the obstacles to treatment of the HIV-1 is its extremely
high genetic variability, which results in many subtypes and CRFs.
According to the epidemiological data, HIV-1 subtypes and CRFs
are very unevenly distributed throughout the world, with the most
widespread being subtypes A, B and C [27–28]. Subtype A viruses
predominate in west and central Africa, and subtype B is the most
common form in Europe, the Americas, Japan, Thailand, and
Australia; Subtype C is the dominant form in southern and eastern
Africa, India, and Nepal and is responsible for about half of
worldwide infections. In China, CRF07_BC, CRF01_AE and
subtype B9 have caused the worst HIV-1 epidemics [29–30].
Because some in vitro and in vivo observations suggest that the
various subtypes may respond differently to certain antiretroviral
drugs [34–38], we have evaluated ABT for its anti-HIV spectrum
by using two large panels of HIV-1 pseudoviruses with their Envs
corresponding to the above diverse variants. Sequence analyses
indicate that these viral Envs exhibit high genetic variations, not
only in gp120 but also in the NHR and CHR of gp41.
Furthermore, we have also evaluated ABT for its inhibitory
activity on a panel of HIV-1 variants that are highly resistant to
T20. The presented results have demonstrated that ABT has
potent and broad antiviral activity against diverse HIV-1 variants,
suggesting its relatively higher genetic barrier for drug-resistance.
Human serum albumin (HSA) constitutes about half of the
blood serum protein and is the most abundant protein in human
plasma. Due to its serum half-life of approximately 20 days and
well distribution in different tissues, it has been used as a drug
carrier for small molecule, peptides and protein-based therapeutics
and shows excellent safety profiles and therapeutic efficacy [38–
43]. ABT was designed to be a long-lasting peptide inhibitor that
can automatically link the serum albumin and exert in vivo anti-
HIV activity after injection [25]. The efficient in vivo protein
binding capacity and the significantly prolonged in vivo half-life of
ABT were verified in the previous studies. Its potent in vivo anti-
HIV activity was also demonstrated by a SCID-hu Thy/Liv
mouse model [25]. Being a molecular mass of 67 Kd, one may
speculate that HSA can impose a steric hindrance to the
accessibility of the NHR target during the pre-hairpin state of
gp41 [44], but it is not the case for HSA-conjugated CHR
peptides. It was observed by in vitro experiments that HSA-
conjugated ABT had a similar anti-HIV activity with the free ABT
peptide (data not shown). Our data also showed that ABT-HSA
conjugates could efficiently block 6-HB formation and membrane
fusion, explaining how ABT can act well after its conjugation to
the serum albumin. Recently, several groups have validated the
accessibility of NHR pre-hairpin intermediate by large molecules,
such as neutralizing antibodies and protein-based inhibitors [45–
46].
Recently, HSA was conjugated to the N- or C-termini of C34
and T20 [24]. It showed that the designed bioconjugates, such as
PC-1505 were essentially equipotent to the parent peptides in vitro
and possessed significantly improved pharmacokinetic profiles and
potent anti-HIV activity in vivo. Differently, ABT peptide was
modified by a MPA molecule in the middle region of its body
(Fig. 1) and could be automatically conjugated in vivo upon
injection [25]. We are wondering how can ABT, after its tight
attachment to HSA, keep its flexibility to interact with the NHR
region and exerts its inhibition on 6-HB? In other words,
positioning of ABT through its middle to a large cargo does not
affect its NHR binding to form a stable 6-HB structure. We are on
the way to determine the crystal structure of ABT-HSA conjugate
in the presence and absence of a NHR peptide, and hopefully, this
study will deliver more detailed information on the antiviral
mechanism of ABT. It should be discussed that the albumin
molecule may also play an active participatory role rather than
only serving as a protein cargo. In fact, the previous studies
demonstrated that the chemically modified albumins are potent
HIV entry inhibitors [47–50]. Furthermore, Jacobs et al [51]
reported that the MPA-modified C34 could serve as a covalent
inhibitor targeting an intermediate conformation of the gp41
during the fusion. It is possible the permanent specific attachment
Table 3. Inhibition of ABT on T20-resistant HIV-1 variants
a.
HIV-1NL4-3
b T20 C34 ABT AZT
IC50 (nM) Fold change
c IC50 (nM) Fold change IC50 (nM) Fold change IC50 (nM) Fold change
WT 62.5611.9 1.0 (8.3) 2.060.6 1.0 (1.8) 1.960.4 1.0 (0.6) 106.7623.2 1.0 (1.8)
D36G 7.561.3 0.1 (1.0) 1.160.1 0.6 (1.0) 3.360.8 1.7 (1.0) 59.465.9 0.6 (1.0)
I37T 300.2655.1 4.8 (40.0) 20.561.7 10.3 (18.6) 7.661.0 4.0 (2.3) 93.5613.5 0.9 (1.6)
V38A 1261.06182.3 20.2 (168.1) 47.2610.8 23.6 (42.9) 8.561.2 4.5 (2.6) 42.369.0 0.4 (0.7)
V38M 645.6657.7 10.3 (86.1) 16.564.2 8.3 (15.0) 8.761.4 4.5 (2.6) 47.863.7 0.5 (0.8)
Q40H 731.4635.2 11.7 (97.5) 39.965.3 20.0 (36.3) 9.762.0 6.5 (2.9) 33.267.2 0.3 (0.6)
N43K 262.3644.4 4.2 (35.0) 26.363.5 13.2 (23.9) 5.960.9 3.1 (1.8) 153.367.4 1.4 (2.6)
D36S/V38M 322.5660.3 5.2 (43.0) 11.361.6 5.7 (10.3) 10.360.9 5.4 (3.1) 40.368.6 0.4 (0.7)
I37T/N43K .3,000.0 .48.0 (.400.0) 261.8647.4 131.9 (238.0) 32.465.9 17.1 (9.8) 138.9614.9 1.3 (2.3)
V38A/N42T .3,000.0 .48.0 (.400.0) 444.36133 222.2 (403.9) 7.861.5 4.1 (2.4) 38.163.7 0.4 (0.6)
L33S .750.0 NA ND NA 2.760.3 NA ND NA
I37V/V38T .750.0 NA ND NA 4.160.8 NA ND NA
aThe data were derived from the results of three independent experiments and are expressed as means 6 standard deviations.
bHIV-1NL4-3-based pseudoviruses were constructed and used in the single-cycle infection assays except that L33S and I37V/V38T are infectious molecular clones of HIV-
1NL4-3.
cBoth wild-type (WT) and D36G were used as reference viruses to calculate the resistance fold-changes.Shown in parentheses are based on the D36G as a reference.
doi:10.1371/journal.pone.0032599.t003
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administration in vivo and thereby improve the long-term
sustainability of peptide inhibitor therapy. It will be interesting
to explore whether ABT has such effect.
In summary, the significance of the present study is threefold.
First, it shows the a-helical and thermostable properties of MPA-
modified peptide fusion inhibitor. Second, it reveals that ABT acts
through a mechanism of blocking fusion-active 6-HB formation
and membrane fusion. Third, it demonstrates that ABT possesses
potent and broad inhibitory activity against diverse HIV-1
subtypes and variants. Therefore, our data indicate that the
chemically modified anti-HIV peptide ABT can serve as an ideal
HIV fusion inhibitor that may possess long-lasting activity. The
information presented by this study is critical for guiding ABT for
its ongoing clinical development.
Materials and Methods
Peptide synthesis
Peptides for ABT, T20, C34, and N36 were synthesized on a
standard solid-phase support, purified by reversed-phase high
pressure liquid chromatography, and verified for purity .95% by
mass spectrometry and amino acid composition. The side chain of
13
th lysine residue of the peptide ABT was protected by
allyloxycarbonyl (Aloc), which allows the specific deprotection
and addition of the linker molecule and MPA. Concentrations of
the peptides were determined by UV absorbance and a
theoretically calculated molar-extinction coefficient M(280 nm) of
5500 M
21 cm
21 and 1490 M
21 cm
21 based on the number of
tryptophan and tyrosine residues (all the peptides tested contain
Trp and/or Tyr), respectively.
HIV-1 Env-expressing plasmids
A panel of plasmids encoding HIV-1 Envs were obtained
through the AIDS Research and Reference Reagent Program
(ARRRP), Division of AIDS, NIAID, NIH, including subtype A
Env clones pSVIII-92RW020.5 and 92UG037.8 from Dr. B.H.
Hahn; subtype B Env clones SC422661.8, TRO.11 and
AC10.0.29 from Drs. D. Montefiori, F. Gao and M. Li,
pRHPA4259.7 and pREJO4541.67 from Drs. B.H. Hahn and
J.F. Salazar-Gonzalez, and pCAAN5342.A2 from Drs. B.H. Hahn
and D.L. Kothe; subtype C Env clones Du172.17 and Du422.1
from Drs. D. Montefiori, F. Gao, S. Abdool Karim and G.
Ramjee, CAP45.2.00.G3 from Drs. L. Morris, K. Mlisana and D.
Montefiori, ZM197M.PB7 from Drs. B.H. Hahn, Y. Li and J.F.
Salazar-Gonzalez, ZM109F.PB4 from Drs. E. Hunter and C.
Derdeyn. Six CRF07_BC Env clones (CH064.20, CH070.1,
CH091.9, CH110.2, CH119.10 and CH120.6) were generous gifts
by Dr. Y. Shao in the Chinese Center for Disease Control and
Prevention, Beijing, China. A panel of Env clones derived from
subtype B9 (B01, B02, B04, and 43-22), CRF01_AE (SHX335.24,
YN192.31, AE01, AE03, GX2010.36, GX11.13, GX2010.36H,
BJ5.11), and CRF07_BC (BC02, BC03, BC05, BC07, BC14,
SC19-15, BJ22-5, YN148R-9, XJ50-6, HB5-3) were kindly
provided by Dr. Y. Wang from the National Institute for the
Control of Pharmaceutical and Biological Products, Beijing,
China.
Cell lines
TZM-bl cells were contributed by J.C. Kappes and X. Wu
through the ARRRP, Division of AIDS, NIAID, NIH. This
reporter cell line stably expresses high levels of CD4, CCR5, and
CXCR4 and contains Tat-responsive reporter genes for firefly
luciferase and b-galactosidase under the control of an HIV-1 long
terminal repeat promoter [52]. HL2/3 cells stably expressing HIV
Gag, Env, Tat, Rev, and Nef proteins were obtained through the
ARRRP, NIH from Drs. B. Felber and G. Pavlakis. 293T cells
were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). All cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) growth medium
(Gibco/Invitrogen) containing 10% heat-inactivated fetal bovine
serum (FBS) at 37uC in humidified air containing 5% CO2. Cells
were harvested using trypsin/EDTA solution (Gibco/Invitrogen).
Circular dichroism (CD) spectroscopy
CD spectroscopy was performed as previously described
[15,26]. Briefly, a C-peptide (ABT, T20 or C34) was incubated
with the equal molar concentration of NHR-derived peptide N36
at 37uC for 30 min. The final peptide concentration was 10 mMi n
PBS buffer (pH 7.2). The isolated N- and C-peptides were also
tested. The CD spectra of these individual peptides and peptide
mixtures were acquired on MOS-450 spectropolarimeter (Bio-
Logic, France) using a 1 nm bandwidth with a 1 nm step
resolution from 190 to 260 nm at room temperature. The spectra
were corrected by subtraction of a blank corresponding to the
solvent. Data were averaged over three accumulations. The a-
helical content was calculated from the CD signal by dividing the
mean residue ellipticity [h] at 222 nm by the value expected for
100% helix formation (233,000 degrees.cm
2.dmol
21) as described
previously [53–54]. The thermal denaturation experiment was
performed by monitoring the change in ellipticity [h] at 222 nm at
the increasing temperature (20–90uC) using temperature control-
ler. The temperature was increased at a rate of 1uC per min; data
were acquired at a 2 nm bandwidth at 222 nm at a frequency of
0.25 Hz. The melting curve was smoothened, and the midpoint of
the thermal unfolding transition (Tm) values were taken as the
maximum of the derivative d[h]222/dT. Tm value was detected at
protein concentration of 1 mM in PBS buffer.
Isothermal Titration Calorimetry (ITC) assay
ITC assay was performed using a ITC200 Microcalorimeter
instrument (MicroCal, USA) as described previously [55]. In brief,
2 mM N36 dissolved in ddH20 was injected into the chamber
containing 200 mM ABT, C34 or T20, respectively. The
experiments were carried out at 25uC. The time between
injections was 240 seconds and the stirring speed was 500 rpm.
The heats of dilution were determined in control experiments by
injecting N36 into ddH20 and subtracted from the heats produced
in the corresponding peptide-peptide binding experiments. Data
acquisition and analysis were performed using MicroCal Origin
software (version 7.0).
Inhibition of 6-HB formation by peptides
A monoclonal antibody specific for the gp41 6-HB (NC-1) was
obtained from Dr. Shibo Jiang through the ARRRP, Division of
AIDS, NIAID, NIH. Inhibitory activity of ABT, T20 and C34 on
the 6-HB formation was measured by a modified ELISA-based
method as previously described [26,32]. Briefly, a 96-well
polystyrene plate (Costar, Corning Inc., Corning, NY) was coated
with NC-1 (2 mg/ml in 0.1 M Tris, pH 8.8). A tested peptide
(ABT, C34 or T20) at graded concentrations was mixed with C34-
biotin (0.1 mM) and incubated with N36 (0.1 mM) at room
temperature for 30 min. The mixture was then added to the
NC-1-coated plate, followed by incubation at room temperature
for 30 min and washing with a washing buffer (PBS containing
0.1% Tween 20) three times. Then streptavidin-labeled horserad-
ish peroxidase (Invitrogen) and the substrate 3,3,5,5- tetramethyl-
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(A450) was measured using an ELISA reader (Bio-Rad).
Cell-cell fusion assay
Cell fusion was monitored using a reporter gene assay based on
activation of HIV LTR-driven luciferase cassette in TZM-bl
(Target) cells by HIV-1 tat from the HL2/3 (Effector) cells. Briefly,
the TZM-bl cells were plated in 96-well clusters (2610
4 per well)
and incubated at 37uC overnight. The target cells were co-
cultured with HL2/3 cells (6610
4/well) for 6 hours at 37uC in the
presence or absence of a tested peptide (ABT, T20 or C34) at
graded concentrations. Luciferase activity was measured using
luciferase assay regents (Promega, Medison, WI) and a Lumines-
cence Counter (Promega) according to the manufacture’s
instructions. Background luminescence in TZM-bl cells was
determined without addition of HL2/3 cells. The percent
inhibition of fusion by the peptides and 50% inhibitory of fusion
concentration (IC50) values were calculated as previously described
[15].
Site-directed mutagenesis
A panel of HIV-1NL4-3 mutants resistant to T20 was generated
as described previously [56]. The mutations were created using
double-stranded DNA templates and selection of mutants with
DpnI. For each mutation, the two primers contained the desired
mutation and occupied the same starting and ending positions on
opposite strands of the plasmid DNA. DNA synthesis was carried
out by PCR in a 50-mL reaction volume using 1 mL of denatured
plasmid template (1 ng/mL), 50 pmol of upper and lower primers
and 5 U of high-fidelity thermostable polymerase PrimeStar
(Takara, Dalian, China). PCR amplification was carried out for
one cycle of denaturation at 98uC for 5 min, then 18 cycles of
98uC for 15 s and 68uC for 15 min, followed a final extension at
72uC for 10 min. The amplicons were treated with the restriction
enzyme DpnI for 1 h at 37uC. DpnI-resistant molecules, which
were rich in the desired mutants, were recovered by transforming
Escherichia coli strain-DH5a to antibiotic resistance. The successful
mutations were confirmed by sequencing.
Inhibition of HIV-1 single-cycle infection
HIV-1 pseudoviruses were generated as described previously
[32,55–56]. Briefly, 293T cells (5610
6 cells in 15 ml of growth
medium in a T-75 culture flask) were cotransfected with 10 mgo f
an Env-expressing plasmid and 20 mg of a backbone plasmid
pSG3deltaEnv that encodes Env-defective, luciferase-expressing
HIV-1 genome using Lipofectamine 2000 reagent (Invitrogen).
Pseudovirus-containing culture supernatants were harvested
48 hours after transfection and filtered by 0.45-mm pore size,
and stored at 280uC in 1-ml aliquots until use. The 50% tissue
culture infectious dose (TCID50) of a single thawed aliquot of each
pseudovirus batch was determined in TZM-bl cells. The antiviral
activity of ABT or T20 was determined using TZM-b1 cells as
described previously [21]. Briefly, the peptides were prepared with
ten series dilutions in a 3-fold stepwise manner and mixed with
100 TCID50 viruses and incubated 1 hour at room temperature.
The mixture was added to TZM-bl cells (10
4/well) and incubation
at 37uC for 48 hours. Luciferase activity was measured using
luciferase assay regents (Promega, Medison, WI) and a Lumines-
cence Counter (Promega) according to the manufacture’s
instructions. The percent inhibition by the peptides and 50%
inhibitory concentration (IC50) values were calculated as previ-
ously described [21].
Inhibition of infectious HIV-1NL4-3 variants
HIV-1 molecular clone NL4-3 carrying L33S or I37V/V38T
mutation [57–58] was kindly provided by Dr. Frank Kirchhoff
from the Institute of Virology, the University of Ulm, Ulm,
Germany. The mutant viruses were generated by transient
transfection of NL4-3 plasmids into 293T cells. The virus stocks
were harvested 48 hours post-transfection and quantified for
TCID50. Inhibition of the peptides (ABT and T20) on the NL4-3
mutants was performed as described for pseudoviruses. In brief,
100 TCID50 viruses were used to infect TZM-bl cells in the
presence or absence of serially diluted peptides. Two days post-
infection, the cells were harvested and lysed in reporter lysis buffer,
and the luciferase activity was measured. The IC50 was calculated
as described above using GraphPad Prism software (GraphPad
Prism software Inc., San Diego, CA).
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